We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fecal Metabolite Profiling Predicts Mortality in Critically Ill Patients

By LabMedica International staff writers
Posted on 23 Jun 2025

Critically ill patients in medical intensive care units (MICUs) often suffer from conditions such as acute respiratory distress syndrome (ARDS) or sepsis, which are linked to reduced diversity of gut microbiota and altered concentrations of microbiome-related metabolites. More...

These metabolites have been associated with patient survival and could represent modifiable factors to improve outcomes. Now, researchers have developed a novel diagnostic tool—a metabolic dysbiosis score (MDS)—based on fecal metabolite profiling that can identify critically ill patients at higher risk of 30-day mortality.

The study, conducted by researchers at the University of Chicago (Chicago, IL, USA), aimed to uncover gut microbiome characteristics and metabolic signatures associated with mortality in patients admitted to the MICU for non–COVID–19 respiratory failure or shock. To develop the tool, the researchers performed a prospective observational cohort study involving 196 critically ill patients. Fecal specimens were collected shortly after ICU admission and analyzed using shotgun metagenomic sequencing to define microbiome composition, along with mass spectrometry to quantify microbiota-derived metabolites. The findings, published in Science Advances, show that individual metabolite levels and microbial compositions in the initial samples did not correlate directly with 30-day mortality

However, a specific combination of metabolite concentrations led to the creation of the MDS from fecal concentrations of 13 specific metabolites found in the first fecal sample after ICU admission. It showed a statistically significant independent association with 30-day mortality, offering a metabolic snapshot that could help clinicians identify patients at greater risk of poor outcomes. Importantly, this approach highlights the functional activity of the microbiome, beyond just taxonomic profiling. The MDS offers a new, non-invasive method to stratify critically ill patients based on their likelihood of survival. It opens the door for targeted interventions, such as microbiome-augmentation strategies, by identifying patients who might benefit most. The researchers suggest that fecal metabolic profiling could guide future clinical trials focused on improving outcomes through modulation of the gut microbiota.


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.